DBV Technologies reports Q2 EPS (34c), consensus (45c)

Reports Q2 revenue $1.2M, consensus $1.68M. “DBV is and always has been dedicated to families in the food allergy community-our future patients are our top priority,” said Daniel Tasse, Chief Executive Officer of DBV Technologies. “We have offered a robust proposal to the FDA with the goal of expediting and finalizing a path forward for Viaskin Peanut in 1-3-year-olds. We believe the proposed labeling solution, which identifies patients to label-in and label-out of treatment with the Viaskin Peanut patch, will provide data-driven instructions to prescribers, and thus optimize Viaskin Peanut treatment for toddlers suffering from peanut allergy. On April 29th, the FDA Office of Vaccine Research and Review stated that non-COVID related backlogs were behind them, that the Division was caught-up, allowing more time for interactions with sponsors. We have indeed seen more engagement from FDA, particularly on CMC and our clinical program. DBV looks forward to continued dialogue with FDA in advancing a regulatory pathway for Viaskin Peanut in 1-3-year-olds.”